London Health Sciences Centre
London, Ontario, Canada
50 recruiting
Showing 1–20 of 118 trials
Recruiting
Phase 4
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Ulcerative Colitis
Takeda60 enrolled49 locationsNCT06095128
Recruiting
PRedictors Of Maladaptive Behaviors in Children Undergoing Procedural SEDation
Procedural Sedation and Analgesia
London Health Sciences Centre Research Institute2,145 enrolled2 locationsNCT07495826
Recruiting
Not Applicable
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
Kidney TransplantationDelayed Graft Function
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's160 enrolledNCT07726134
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Kidney Disease
Takeda347 enrolled175 locationsNCT06963827
Recruiting
Phase 3
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
Hepatocellular Carcinoma (HCC)
Hamilton Health Sciences Corporation30 enrolledNCT07027436
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled555 locationsNCT06492616
Recruiting
Phase 3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled185 locationsNCT06282575
Recruiting
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation466 enrolled178 locationsNCT07214779
Recruiting
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Pain
Boston Scientific Corporation4,800 enrolled118 locationsNCT01719055
Recruiting
Phase 3
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled124 locationsNCT06846671
Recruiting
Phase 3
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
Open tíbia Fracture
University of Maryland, Baltimore312 enrolled34 locationsNCT05615844
Recruiting
Phase 4
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Crohn's Disease
Takeda50 enrolled53 locationsNCT06045754
Recruiting
Not Applicable
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
End Stage Renal DiseaseChronic Kidney Disease Stage 5
University of Manitoba340 enrolled5 locationsNCT05726526
Recruiting
Phase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Eli Lilly and Company252 enrolled147 locationsNCT07186101
Recruiting
Not Applicable
MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
Femoral Neck Fractures
University of Southern California600 enrolled16 locationsNCT07244211
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled186 locationsNCT06937099
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled189 locationsNCT06937086
Recruiting
Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled225 locationsNCT06226883
Recruiting
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Multiple Myeloma
Canadian Myeloma Research Group75 enrolled7 locationsNCT05272826
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled124 locationsNCT07258511